ST PHARM proudly announces its participation in the 2024 Drug, Chemical & Associated Technologies (DCAT) Week, held at the Intercontinental New York Barclay Hotel in New York from the 18th to the 21st of March (local time).
DCAT Week, a prestigious event in the pharmaceutical bio sector with a history spanning 150 years, originated in 1890 under the auspices of the New York Chamber of Commerce. Serving as a vital platform for fostering partnerships and driving innovation within the industry, DCAT Week continues to play a pivotal role in shaping the future of pharmaceuticals.
As a key participant, ST PHARM has been honored with the opportunity to make announcements at the DCAT Member Company Announcement Forum, an official event of DCAT. During this forum, ST PHARM provided updates on its ongoing second oligo expansion and showcased the core capabilities of its RNA platform technology.
Additionally, ST PHARM engaged in discussions with existing Oligo business customers regarding project volumes for the first half of the year, demonstrating its commitment to customer satisfaction and project excellence.
Notably, ST PHARM has focused on strengthening its global network and attracting new customers, while actively promoting environmentally friendly design and enhancing efficiency through automation in new production agreements.
An official from ST PHARM commented, "We have conducted face-to-face meetings with high-level officials from over 20 existing and potential customers, continuing discussions on partnerships in various fields such as synthetic new drugs, Oligo, and mRNA. We are committed to showcasing ST PHARM’s vision and business competitiveness on the global stage while strengthening our partnerships."
ST PHARM's participation in the 2024 DCAT Week heralds a new era of innovation and collaboration in the pharmaceutical industry, reinforcing its position as a leader in cutting-edge technologies and customer-centric solutions.
DCAT Week, a prestigious event in the pharmaceutical bio sector with a history spanning 150 years, originated in 1890 under the auspices of the New York Chamber of Commerce. Serving as a vital platform for fostering partnerships and driving innovation within the industry, DCAT Week continues to play a pivotal role in shaping the future of pharmaceuticals.
As a key participant, ST PHARM has been honored with the opportunity to make announcements at the DCAT Member Company Announcement Forum, an official event of DCAT. During this forum, ST PHARM provided updates on its ongoing second oligo expansion and showcased the core capabilities of its RNA platform technology.
Additionally, ST PHARM engaged in discussions with existing Oligo business customers regarding project volumes for the first half of the year, demonstrating its commitment to customer satisfaction and project excellence.
Notably, ST PHARM has focused on strengthening its global network and attracting new customers, while actively promoting environmentally friendly design and enhancing efficiency through automation in new production agreements.
An official from ST PHARM commented, "We have conducted face-to-face meetings with high-level officials from over 20 existing and potential customers, continuing discussions on partnerships in various fields such as synthetic new drugs, Oligo, and mRNA. We are committed to showcasing ST PHARM’s vision and business competitiveness on the global stage while strengthening our partnerships."
ST PHARM's participation in the 2024 DCAT Week heralds a new era of innovation and collaboration in the pharmaceutical industry, reinforcing its position as a leader in cutting-edge technologies and customer-centric solutions.